Background We conducted a randomized, placebo-controlled, double-blind trial to determine
whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–…

PURPOSE: To evaluate whether treatment with single-agent docetaxel would result in longer
survival than would best supportive care in patients with non–small-cell lung cancer who …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). …

Purpose To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients
with advanced non—small-cell lung cancer (NSCLC) previously treated with chemotherapy. …

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–mutated,
stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or …

This meta-analysis of individual patient data concluded that postoperative cisplatin-based
chemotherapy significantly improved survival compared with no chemotherapy in patients with …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs
overall survival among patients with completely resected early-stage non–small-cell lung …

Background Two phase II trials in patients with previously-treated advanced non-small-cell
lung cancer suggested that gefitinib was efficacious and less toxic than was chemotherapy. …